280 related articles for article (PubMed ID: 33068904)
1. Matrix metalloproteinases deregulation in amyotrophic lateral sclerosis.
Sánchez-Torres JL; Yescas-Gómez P; Torres-Romero J; Espinosa OR; Canovas LL; Tecalco-Cruz ÁC; Ponce-Regalado MD; Alvarez-Sánchez ME
J Neurol Sci; 2020 Dec; 419():117175. PubMed ID: 33068904
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS).
Łukaszewicz-Zając M; Mroczko B; Słowik A
J Neural Transm (Vienna); 2014 Nov; 121(11):1387-97. PubMed ID: 25047909
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
4. MyomiRs and their multifaceted regulatory roles in muscle homeostasis and amyotrophic lateral sclerosis.
Giagnorio E; Malacarne C; Mantegazza R; Bonanno S; Marcuzzo S
J Cell Sci; 2021 Jun; 134(12):. PubMed ID: 34137441
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of matrix metalloproteinases in serum of patients with amyotrophic lateral sclerosis with pattern recognition methods.
Sokolowska B; Jozwik A; Niebroj-Dobosz I; Janik P; Kwiecinski H
J Physiol Pharmacol; 2009 Nov; 60 Suppl 5():117-20. PubMed ID: 20134051
[TBL] [Abstract][Full Text] [Related]
6. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases.
Lorenzl S; Albers DS; LeWitt PA; Chirichigno JW; Hilgenberg SL; Cudkowicz ME; Beal MF
J Neurol Sci; 2003 Mar; 207(1-2):71-6. PubMed ID: 12614934
[TBL] [Abstract][Full Text] [Related]
7. Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS).
Fang L; Huber-Abel F; Teuchert M; Hendrich C; Dorst J; Schattauer D; Zettlmeissel H; Wlaschek M; Scharffetter-Kochanek K; Tumani H; Ludolph AC; Brettschneider J
J Neurol Sci; 2009 Oct; 285(1-2):62-6. PubMed ID: 19523650
[TBL] [Abstract][Full Text] [Related]
8. Advances in genetics research in the pathogenesis of amyotrophic lateral sclerosis.
Wang Y; Yi H; Liao Q; Bi F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 45(12):1483-1489. PubMed ID: 33473007
[TBL] [Abstract][Full Text] [Related]
9. Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives.
Behl T; Kaur G; Sehgal A; Bhardwaj S; Singh S; Buhas C; Judea-Pusta C; Uivarosan D; Munteanu MA; Bungau S
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573368
[TBL] [Abstract][Full Text] [Related]
10. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression.
Bruneteau G; Simonet T; Bauché S; Mandjee N; Malfatti E; Girard E; Tanguy ML; Behin A; Khiami F; Sariali E; Hell-Remy C; Salachas F; Pradat PF; Fournier E; Lacomblez L; Koenig J; Romero NB; Fontaine B; Meininger V; Schaeffer L; Hantaï D
Brain; 2013 Aug; 136(Pt 8):2359-68. PubMed ID: 23824486
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs in amyotrophic lateral sclerosis: from pathogenetic involvement to diagnostic biomarker and therapeutic agent development.
Wang L; Zhang L
Neurol Sci; 2020 Dec; 41(12):3569-3577. PubMed ID: 33006054
[TBL] [Abstract][Full Text] [Related]
12. Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases.
Brkic M; Balusu S; Libert C; Vandenbroucke RE
Mediators Inflamm; 2015; 2015():620581. PubMed ID: 26538832
[TBL] [Abstract][Full Text] [Related]
13. Metalloproteinase alterations in the bone marrow of ALS patients.
Bossolasco P; Cova L; Calzarossa C; Servida F; Mencacci NE; Onida F; Polli E; Lambertenghi Deliliers G; Silani V
J Mol Med (Berl); 2010 Jun; 88(6):553-64. PubMed ID: 20091292
[TBL] [Abstract][Full Text] [Related]
14. The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice.
Lorenzl S; Narr S; Angele B; Krell HW; Gregorio J; Kiaei M; Pfister HW; Beal MF
Exp Neurol; 2006 Jul; 200(1):166-71. PubMed ID: 16516196
[TBL] [Abstract][Full Text] [Related]
15. Purinergic P2X
Mckenzie ADJ; Garrett TR; Werry EL; Kassiou M
ACS Chem Neurosci; 2022 May; 13(10):1479-1490. PubMed ID: 35512313
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
Galboiz Y; Shapiro S; Lahat N; Rawashdeh H; Miller A
Ann Neurol; 2001 Oct; 50(4):443-51. PubMed ID: 11601495
[TBL] [Abstract][Full Text] [Related]
17. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
[TBL] [Abstract][Full Text] [Related]
18. Prospects for gene replacement therapies in amyotrophic lateral sclerosis.
Giovannelli I; Higginbottom A; Kirby J; Azzouz M; Shaw PJ
Nat Rev Neurol; 2023 Jan; 19(1):39-52. PubMed ID: 36481799
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients.
Lim GP; Backstrom JR; Cullen MJ; Miller CA; Atkinson RD; Tökés ZA
J Neurochem; 1996 Jul; 67(1):251-9. PubMed ID: 8666998
[TBL] [Abstract][Full Text] [Related]
20. Consideration of gravity as a possible etiological factor in amyotrophic lateral sclerosis.
Akaishi T; Takahashi T; Abe M; Aoki M; Ishii T
Med Hypotheses; 2019 Nov; 132():109369. PubMed ID: 31442918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
